For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

The cancer stem cell (CSC) concept derives from the fact that cancers are dysregulated
tissue clones whose continued propagation is vested in a biologically distinct subset of cells …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to
kinase inhibitors and responsible for minimal residual disease in treated patients. We …

Chronic myeloid leukemia (CML) originates in a hematopoietic stem cell (HSC) transformed
by the breakpoint cluster region (BCR)-abelson (ABL) oncogene and is effectively treated …

We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous
leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long …

The discovery of recurrent gene fusions in a majority of prostate cancers has important
clinical and biological implications in the study of common epithelial tumours. Gene fusion …

MicroRNAs and heterogeneous ribonucleoproteins (hnRNPs) are posttranscriptional gene
regulators that bind mRNA in a sequence-specific manner. Here, we report that loss of miR …